Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance

Area of Science:

• Neurology
• Genetics
• Pediatrics

Background:

• Spinal muscular atrophy (SMA) is a severe autosomal recessive neuromuscular disorder caused by the loss of function of the survival motor neuron gene (SMN1).
• SMA affects alpha motor neurons, leading to progressive hypotonia and muscle weakness, with a significant carrier frequency and incidence.
• The SMN2 gene acts as a modifier, with its copy number influencing the clinical phenotype.

Purpose of the Study:

• To review the diagnosis, carrier screening, and recent therapeutic advancements for Spinal Muscular Atrophy (SMA).
• To highlight the importance of genetic testing and newborn screening for early intervention in SMA.
• To discuss the mechanisms and impact of newly approved FDA treatments for SMA.

Main Methods:

• Review of genetic mutations in SMN1 and the role of SMN2 copy number.
• Analysis of population-based carrier screening strategies for SMA.
• Examination of FDA-approved treatments: Nusinersen, Onasemnogene abeparvovec, and Risdiplam.
• Evaluation of the success of newborn screening programs for SMA.

Main Results:

• The homozygous deletion of SMN1 exon 7 is a common diagnostic marker for SMA.
• SMN2 copy number is a critical predictor of SMA clinical severity.
• Approved therapies target SMN protein levels through antisense oligonucleotides, gene therapy, or small molecule splicing modification.
• Newborn screening enables pre-symptomatic treatment, significantly improving clinical outcomes.

Conclusions:

• Early diagnosis through genetic testing and newborn screening is vital for effective SMA management.
• Recent therapeutic breakthroughs offer new hope for individuals with SMA, targeting the underlying genetic defect.
• Understanding the role of SMN2 is key to predicting disease progression and treatment response in SMA.